◆英語タイトル:National Cancer Center Hospital - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9392
◆発行会社(調査会社):
GlobalData
◆発行日:2018年11月
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
National Cancer Center Hospital (NCC) is a healthcare service provider that offers cancer care services. The hospital provides cancer diagnosis and treatment services. It provides services such as examination, treatment, patient care services and co-medical support. NCC provides diagnosis and treatments by utilizing advanced screening and examination protocols with high-tech systems and equipment. It offers services in the areas of thoracic surgery, breast surgery, palliative care, chemotherapy, neurosurgery, ophthalmic oncology, head and neck oncology, endoscopic treatment and radiotherapy, among others. The hospital also provides consultation and examinations services by advanced computer system in the clinics. NCC is headquartered in Tokyo, Japan.
National Cancer Center Hospital – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
National Cancer Center Hospital, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
National Cancer Center Hospital, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
National Cancer Center Hospital, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
National Cancer Center Hospital, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
National Cancer Center Hospital, Medical Devices Deals, 2012 to YTD 2018 9
National Cancer Center Hospital, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
National Cancer Center Hospital, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
KAN Research Institute Enters into Development Agreement with Six Research Organizations 12
National Cancer Center, JVCKENWOOD, Sysmex and Daiichi Sankyo Enter into Agreement 14
Oncolys BioPharma Enters into Agreement with National Cancer Center Hospital 15
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 16
VLP Therapeutics Enters into Research Agreement with National Cancer Center Hospital 18
National Cancer Center and Takeda Pharma to Develop Anti-Cancer Agents 19
Chiome Bioscience Enters Into Co-Development Agreement With National Cancer Center Hospital 20
Daiichi Sankyo Enters Into Co-Development Agreement With National Cancer Center Hospital East 21
National Cancer Center Hospital – Key Competitors 22
National Cancer Center Hospital – Key Employees 23
National Cancer Center Hospital – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Strategy And Business Planning 25
Jun 01, 2018: NCC Establishes Center for Cancer Genomics and Advanced Therapeutics (C-CAT) to Aggregate and Manage Information on Cancer Genomic Medicine and Promote Its Use 25
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27
List of Tables
National Cancer Center Hospital, Pharmaceuticals & Healthcare, Key Facts 2
National Cancer Center Hospital, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
National Cancer Center Hospital, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
National Cancer Center Hospital, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
National Cancer Center Hospital, Deals By Therapy Area, 2012 to YTD 2018 8
National Cancer Center Hospital, Medical Devices Deals, 2012 to YTD 2018 9
National Cancer Center Hospital, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
KAN Research Institute Enters into Development Agreement with Six Research Organizations 12
National Cancer Center, JVCKENWOOD, Sysmex and Daiichi Sankyo Enter into Agreement 14
Oncolys BioPharma Enters into Agreement with National Cancer Center Hospital 15
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 16
VLP Therapeutics Enters into Research Agreement with National Cancer Center Hospital 18
National Cancer Center and Takeda Pharma to Develop Anti-Cancer Agents 19
Chiome Bioscience Enters Into Co-Development Agreement With National Cancer Center Hospital 20
Daiichi Sankyo Enters Into Co-Development Agreement With National Cancer Center Hospital East 21
National Cancer Center Hospital, Key Competitors 22
National Cancer Center Hospital, Key Employees 23
National Cancer Center Hospital, Other Locations 24
National Cancer Center Hospital, Subsidiaries 24
List of Figures
National Cancer Center Hospital, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
National Cancer Center Hospital, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
National Cancer Center Hospital, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
National Cancer Center Hospital, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
National Cancer Center Hospital, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
National Cancer Center Hospital, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
National Cancer Center Hospital, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
National Cancer Center Hospital, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
National Cancer Center Hospital, Medical Devices Deals, 2012 to YTD 2018 9